Breye Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy
25 Jan 2024 //
PR NEWSWIRE
Golgi and Breye announce closing of P2X7 receptor antagonist program transfer
25 Jul 2023 //
PR NEWSWIRE
Breye Therapeutics Strengthens Management Team and Board
19 Apr 2023 //
PR NEWSWIRE